NEW YORK, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

Mercury Systems, Inc. (NASDAQGS: MRCY) Class Period: October 24, 2017 - April 24, 2018 Lead Plaintiff Deadline: September 10, 2018 Join the action: http://www.zlk.com/pslra-d/mercury-systems?wire=3

Allegations: Mercury Systems, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (i) Mercury’s decision to in-source processing was adversely impacting Mercury’s operating margins and free cash-flow generation and conversion; (ii) Mercury’s model was becoming structurally more working capital intensive; (iii) as a result of the foregoing, Mercury’s public statements were materially false and misleading at all relevant times.

To learn more about the MRCY class action contact jlevi@levikorsinsky.com.

Glencore plc (OTCMKTS: GLNCY, GLCNF) Class Period: September 30, 2016 - July 2, 2018 Lead Plaintiff Deadline: September 7, 2018 Join the action: http://www.zlk.com/pslra-d/glencore?wire=3

Allegations: During the class period, Glencore plc made materially false and/or misleading statements and/or failed to disclose that: (i) Glencore’s conduct would subject it to heightened scrutiny by U.S. and foreign government bodies resulting in investigations into the company’s compliance with money laundering and bribery laws, as well as the Foreign Corrupt Practices Act; and (ii) as a result, defendants’ statements about Glencore’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times. On May 18, 2018, Bloomberg reported that the U.K.'s Serious Fraud Office was preparing to open a formal bribery investigation into Glencore. Then on July 3, 2018, Glencore disclosed that the U.S. Department of Justice issued its subsidiary a subpoena to produce documents and other records in connection with its compliance with U.S. money laundering statutes and the Foreign Corrupt Practices Act.

To learn more about the GLNCY class action contact jlevi@levikorsinsky.com.

National Beverage Corp. (NASDAQ: FIZZ) Class Period: July 17, 2014 - July 3, 2018 Lead Plaintiff Deadline: September 17, 2018 Join the action: http://www.zlk.com/pslra-d/fizz-lawsuit?wire=3

Allegations: National Beverage Corp. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) National Beverage's sales claims and its supposed "proprietary techniques" lacked a verifiable basis; (2) the Company's Chairman and CEO engaged in a pattern of sexual misconduct between 2014 and 2016; and (3) as a result, National Beverage's public statements were materially false and misleading at all relevant times. On May 4, 2017, National Beverage issued a press release stating that it “employs methods that no other company does in this area—VPO (velocity per outlet) and VPC (velocity per capita).” National Beverage asserted that it “utilize[s] two proprietary techniques to magnify these measures and this creates growth never before thought possible.” Then on June 26, 2018 the Wall Street Journal reported that National Beverage had declined to provide the U.S. Securities and Exchange Commission with requested sales figures to clarify their sales claims. Then on July 3, 2018, the Wall Street Journal published an article reporting that two pilots had filed lawsuits alleging that National Beverage's CEO had sexually harassed them.

To learn more about the FIZZ class action contact jlevi@levikorsinsky.com.

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Class Period: April 29, 2016 - July 9, 2018 Lead Plaintiff Deadline: September 17, 2018 Join the action: http://www.zlk.com/pslra-d/acadia?wire=3

Allegations: ACADIA Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) adverse events and safety concerns related to NUPLAZID threatened the drug’s initial and continuing FDA approval; (2) ACADIA engaged in business practices likely to attract regulatory scrutiny; and (3) as a result, defendants’ statements about ACADIA’s business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To learn more about the ACAD class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Levi & Korsinsky, LLPJoseph E. Levi, Esq.30 Broad Street - 24th FloorNew York, NY 10004 jlevi@levikorsinsky.com Tel: (212) 363-7500Toll Free: (877) 363-5972Fax: (212) 363-7171 www.zlk.com